Table 4 Best overall response by Response Evaluation Criteria in Solid Tumors
| Â | All specimens | With bevacizumab treatment | Without bevacizumab treatment | ||||||
|---|---|---|---|---|---|---|---|---|---|
Serum PRTN3 low (n=34) | Serum PRTN3 high (n=45) | P-value | Serum PRTN3 low (n=10) | Serum PRTN3 high (n=19) | P-value | Serum PRTN3 low (n=24) | Serum PRTN3 high (n=26) | P-value | |
Best overall response | Â | Â | <0.001 | Â | Â | <0.001 | Â | Â | 0.004 |
Partial response | 21 (61.8) | 5 (11.1) | Â | 8 (80.0) | 2 (10.5) | Â | 13 (54.2) | 3 (11.5) | Â |
Stable disease | 10 (29.4) | 27 (60.0) | Â | 2 (20.0) | 13 (68.4) | Â | 8 (33.3) | 14 (53.9) | Â |
Progressive disease | 3 (8.8) | 13 (28.9) | Â | 0 | 4 (21.1) | Â | 3 (12.5) | 9 (34.6) | Â |